Unstructured recombinant polymers and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/24
C40B-050/18
출원번호
UP-0715276
(2007-03-06)
등록번호
US-7855279
(2011-02-14)
발명자
/ 주소
Schellenberger, Volker
Stemmer, Willem P.
Wang, Chia-wei
Scholle, Michael D.
Popkov, Mikhail
Gordon, Nathaniel C.
Crameri, Andreas
출원인 / 주소
Amunix Operating, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
15인용 특허 :
78
초록▼
The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention al
The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
대표청구항▼
What is claimed is: 1. An isolated unstructured recombinant polypeptide (URP) comprising at least 40 contiguous amino acids, wherein (a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes at least 8
What is claimed is: 1. An isolated unstructured recombinant polypeptide (URP) comprising at least 40 contiguous amino acids, wherein (a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes at least 80% of the total amino acids of the URP, and the remainder, when present, consists of arginine or lysine, and the remainder does not contain methionine, cysteine, asparagine, and glutamine; (b) wherein said URP comprises at least three different types of amino acids; (c) at least 50% of the at least 40 contiguous amino acids in said URP are devoid of secondary structure as determined by Chou-Fasman algorithm; (d) wherein the URP has a Tepitope score less than −4; and wherein incorporation of the URP into a heterologous protein results in a fusion protein having at least a 2-fold increase in apparent molecular weight of the fusion protein as compared to the protein lacking said URP, wherein the apparent molecular weight is approximated by size exclusion chromatography, and wherein the fusion protein exhibits an increased half-life as compared to the protein lacking said URP. 2. The unstructured recombinant polypeptide (URP) of claim 1, wherein said URP has an in vitro serum degradation half-life greater than about 24 hours. 3. The URP of claim 1, wherein the URP is selected for incorporation into an N- and/or C-terminus of a heterologous protein to create a monomeric fusion protein, and wherein upon incorporation the URP into a heterologous protein, said heterologous protein exhibits a longer serum half-life and/or higher solubility as compared to the corresponding protein that is deficient in said URP. 4. The URP of claim 1, wherein upon incorporation of the URP into to an N- and/or C-terminus of a heterologous protein to create a monomeric fusion protein, said heterologous protein exhibits a serum secretion half-life that is at least two times longer as compared to the corresponding protein that is deficient in said URP. 5. The URP of claim 1, wherein one of the amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) alone constitutes at least 20% of the total amino acids of the URP. 6. The URP of claim 1, wherein one of the amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) alone constitutes at least 30% of the total amino acids of the URP. 7. The URP of claim 1, wherein the URP comprises at least 100 contiguous amino acids. 8. The URP of claim 1, wherein the URP comprises at least 200 contiguous amino acids. 9. The URP of claim 1, wherein the URP comprises at least 400 contiguous amino acids. 10. The URP of claim 1, wherein any one type of amino acid is no more than 30% of the total amino acids of the URP. 11. The URP of claim 4, wherein the heterologous protein is a growth hormone. 12. The URP of claim 11, wherein the growth hormone is human growth hormone. 13. The URP of claim 4, wherein the heterologous protein is a glucagon.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (78)
Bernstein Bruce S. (Somerville NJ) Hyman Seymour (New York NY) Kapoor Ramesh C. (Seaford DE), Activated polymer materials and process for making same.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Composition for delivering bioactive agents for immune response and its preparation.
Qiu, Yihong; Bollinger, J. Daniel; Cheskin, Howard S.; Dutta, Sandeep; Engh, Kevin R.; Poska, Richard P., Controlled release formulation of divalproex sodium.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Tice, Thomas R.; Lewis, Danny H.; Cowsar, Donald R.; Beck, Lee R., Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Turner Terry L. (Charlottesville VA) Howards Stuart S. (Charlottesville VA), Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
D\Arrigo Joseph S. (Farmington CT), Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and the.
Andrew S. Janoff ; Thomas D. Madden CA; Pieter R. Cullis CA; John J. Kearns ; Anthony G. Durning, Methods of preparing low-toxicity drug-lipid complexes.
Tice, Thomas R.; Dillon, Deborah L.; Mason, David W.; McRae-McFarlane, Amanda; Dahlstrom, Annica B., Microcapsules for administration of neuroactive agents.
Harrison Juan M. E. (Mountain View CA) Barclay Brian L. (Sunnyvale CA) Childers Jerry D. (Menlo Park CA) Wright Jeri D. (Dublin CA) Place Virgil A. (Kawaihae HI) Wong Patrick S. (Palo Alto CA), Oral osmotic device with hydrogel driving member.
Popescu Mircea C. ; Weiner Alan L. ; Recine Marie S. ; Janoff Andrew S. ; Estis Leonard ; Keyes Lynn D. ; Alving Carl R., Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use.
Edward M. Rudnic ; Beth A. Burnside ; Henry H. Flanner ; Sandra E. Wassink ; Richard A. Couch ; Jill E. Pinkett, Soluble form osmotic dose delivery system.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Rudnic, Edward M.; Burnside, Beth A.; Flanner, Henry H.; Wassink, Sandra E.; Couch, Richard A.; Pinkett, Jill E., Soluble form osmotic dose delivery system.
D\Arrigo Joseph S. (23A Brickyard Rd. Farmington CT 06032), Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures.
Wheatley Margaret A. (Norristown PA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for controlled release of biologically active compounds.
Adler-Moore Jill ; Gamble Ronald C. ; Proffitt Richard T., Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics.
Schellenberger, Volker; Stemmer, Willem P.; Wang, Chia-Wei; Scholle, Michael D.; Gordon, Nathaniel C.; Crameri, Andreas; Popkov, Mikhail, Biologically active proteins having increased in vivo and/or in vitro stability.
Schellenberger, Volker; Stemmer, Willem P.; Geething, Nathan C.; To, Wayne; Silverman, Joshua; Wang, Chia-wei; Spink, Benjamin, Coagulation factor IX compositions and methods of making and using same.
Schellenberger, Volker; Stemmer, Willem P.; Geething, Nathan C.; To, Wayne; Silverman, Joshua; Wang, Chia-wei; Spink, Benjamin, Coagulation factor IX compositions and methods of making and using same.
Schellenberger, Volker; Stemmer, Willem P.; Geething, Nathan C.; To, Wayne; Silverman, Joshua; Wang, Chia-wei; Spink, Benjamin, Coagulation factor IX compositions and methods of making and using same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.